Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Pharmaceutical company (renamed from Jubilant Life Sciences after the Ingrevia demerger) with US-centric businesses: radiopharmaceuticals (nuclear imaging products and a US radiopharmacy network), allergy immunotherapy, CDMO of sterile injectables through facilities in Spokane (US) and Montreal (Canada), and generics/API operations in India. Also runs a drug-discovery services arm and contract manufacturing for large innovator clients.
One of the few Indian pharma companies with a meaningful radiopharmaceuticals and North American sterile-injectables CDMO franchise.
Jubilant Pharmova Ltd. is a constituent of NIFTY 500, NIFTY SMALLCAP 250. See where it sits on the market heatmap →
Consolidated annual figures taken from Jubilant Pharmova Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 25.15 | 52.99 | 4.87 |
| Book value / share (₹) | 449.09 | 394.85 | 343.11 |
| Return on equity | 5.6% | 13.4% | 1.4% |
| Return on capital employed | 6.3% | 7.6% | 5.4% |
| Operating margin | 9.9% | 11.1% | 7.7% |
| Net margin | 4.8% | 11.6% | 1.1% |
| EBITDA | ₹1,260 Cr | ₹1,174 Cr | ₹901 Cr |
| Free cash flow | ₹-222 Cr | ₹-44 Cr | ₹74 Cr |
| Total debt | ₹3,220 Cr | ₹2,437 Cr | ₹3,414 Cr |
| Debt to equity | 0.45 | 0.39 | 0.63 |
| Interest coverage | 3.9 | 3.4 | 1.9 |
| Current ratio | 1.62 | 1.62 | 1.92 |
| Shares outstanding | 15,80,00,000 | 15,80,00,000 | 15,80,00,000 |
Open the full income statement, balance sheet and cash flow for JUBLPHARMA →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.